InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February 16, 2017, InspireMD, Inc. (the Company) issued a
press release announcing its financial and operating results for
the fourth quarter and year ended December 31, 2016, and
reporting that it received an audit opinion with a going concern
qualification paragraph from its independent registered public
accounting firm. A copy of this press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, that is furnished to this Item 2.02 shall not be deemed to
be filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, and shall not be
incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item 8.01 Other Events.
Termination Notice
As initially reported by the Company in a Current Report on Form
8-K filed with the Securities and Exchange Commission on August
5, 2015, InspireMD, Ltd. (InspireMD), a wholly owned subsidiary
of the Company, entered into a distribution agreement (the
Distribution Agreement) with Penumbra, Inc. (Penumbra), to which
Penumbra would act as the exclusive distributor of the Companys
CGuard carotid embolic prevention system products (the Products)
in Austria, France, Sweden, Denmark, Norway, Finland, Estonia,
Lithuania, Portugal, Switzerland and the United Kingdom and
Ireland.
On February 15, 2017, the Company received a notice of
termination (the Termination Notice) of the Distribution
Agreement from Penumbra notifying the Company that the
Distribution Agreement will be terminated effective April 16,
2017. InspireMD and Penumbra have agreed to use commercially
reasonable efforts to transition distribution of the Products at
the time, in the manner, and to the persons or entities
designated by InspireMD.
Change in Address of Principal Executive Offices
Effective as of February 16, 2017, the Company changed its
principal executive office address to 4 Menorat Hamaor St., Tel
Aviv, Israel, 6744832. The new telephone number for the Company
is (888) 776-6804.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit Number | Description | |
| 99.1 | Earnings release dated February 16, 2017 |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet mesh and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard coronary product, MGuard Prime Embolic Protection System (MGuard Prime EPS), is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session down -0.13 at 2.16 with 44,563 shares trading hands.